Table 2.
Characteristics of Enrolled Participants Who Were Sputum Culture Positive and/or Sputum Xpert Ultra Positive for Mycobacterium tuberculosis: Clinic and Community Survey
| MGIT Positive Only | Xpert Ultra Positive Only | ||
|---|---|---|---|
| Characteristics | Clinic (n = 20) | Community (n = 58) | Community (n = 20) |
| Age, median (IQR), y | 37 (32-46) | 48 (30-64) | 53 (43-60) |
| Male, n (%) | 9 (45.0) | 28 (48.0) | 12 (60.0) |
| MUAC, median (IQR), cm | 25.6 (23.9-26.0) | 27.0 (24.0-30.0) | 28.0 (26.0-30.0) |
| TB treatment history, n (%) | |||
| On treatment | 2 (10.0) | 4 (6.9) | 4 (20.0) |
| Previously treated | 5 (25.0) | 6 (10.3) | 11 (55.0) |
| No history | 13 (65.0) | 48 (82.2) | 5 (25.0) |
| HIV status, n (%) | |||
| Negative | 5 (25.0)a | 31 (53.4) | 10 (50.0) |
| Positive | 15 (75.0)a | 26 (44.8) | 10 (50.0) |
| On ART | 15 (100.0)a | 21 (80.8) | 9 (90.0) |
| ≥1 TB symptom, n (%) | 6 (30.0) | 13 (22.4) | 3 (15.0) |
| TB resistance profile, n (%) | |||
| Rifampicin mono-resistance | 1 (5.0) | 2 (3.4) | 2 (10.0)b |
| Multidrug resistance | 4 (25.0) | 9 (15.5) | … |
| Follow-up TB tests, n (%) | |||
| Positive | 12 (60.0) | … | … |
| Negative | 8 (40.0) | … | … |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; MGIT, Mycobacterial Growth Indicator Tube; MUAC, midupper arm circumference; TB, tuberculosis; Xpert Ultra, Xpert MTB/RIF Ultra assay (Cepheid).
Self-report and clinical record review.
Rifampicin resistance detected.